疏肝解郁胶囊联合不同抗抑郁药治疗难治性抑郁症的效果  

Clinical efficacy of Shugan Jieyu capsule combined with different anti-depressants in the treatment of resistant depression

作　　者：陈红昊[1] 林虹[1] 杜建艳[1] 左津淮[1] 安旭光[1] CHEN Hong-hao(Anding Hospital of Tianjin,Tianfin,-300222,China)

机构地区：[1]天津市安定医院,300222

出　　处：《齐齐哈尔医学院学报》2018年第7期755-757,共3页Journal of Qiqihar Medical University

摘　　要：目的对比疏肝解郁分别联合文拉法辛和米氮平治疗难治性抑郁症的临床效果及安全性,以指导患者用药。方法采用随机数字表法将80例符合《国际疾病分类(第10版)》(ICD-10)的难治性抑郁患者分成疏肝解郁联合文拉法辛组(A组)和疏肝解郁联合米氮平组(B组)2组,每组40例,在疏肝解郁同时分别给予文拉法辛和米氮平治疗,疗程均为12周,分别在治疗前和治疗2、4、8、12周末采用汉密尔顿抑郁量表17(HAMD-17)评定疗效,采用副反应量表(TESS)评定治疗后不良反应。结果治疗12周后A组和B组有效率分别为87.5%和80.0%(P>0.05);治疗第4、8、12周后,A组HAMD评分均较B组低(P<0.05)。结论疏肝解郁联合文拉法辛或米氮平对治疗难治性抑郁症疗效相同,安全性好。Objective To compare the effect and safety of Shugan Jieyu capsule combined with Venlafaxine and Mirtazapine separately in the treatment of treatment resistant depression（ TRD）,which may be useful for guiding drug-use in patients. Methods 80 patients met the diagnostic criteria of International Classification of Disease,tenth edition（ ICD-10）,were randomly divided into A group（ treated with Shugan Jieyu capsule combined with Venlafaxine,n = 40） and B group（ treated by Shugan Jieyu capsule combined with Mirtazapine,n = 40）. The treatment lasted for 12 weeks. Evaluating the efficacy by Hamilton Depression Rating Scale-17（ HAMD-17）,and evaluating the untoward effect by Treatment Emergent Symptom Scale（ TESS） at the time points： before treatment,2 nd,4 th,8 th,and 12 th weekend after treatment.Results After treatment for 12 weeks,the effective rates of two groups were 87.5% and 80.0% respectively,the difference was not statistically significant（ P0.05）. After treatment for 4,8,and 12 weeks,scores of HAMD in the A group were significantly lower than the B group（ P0.05）.Conclusions Shugan Jieyu capsule combined with Venlafaxine or Mirtazapine performs equivalent effect and safety in the treatment of TRD.

关 键 词：疏肝解郁 文拉法辛 米氮平 难治性抑郁症 FT3 

分 类 号：R285[医药卫生—中药学]